Ongoing, planned and completed studies

Over the past 20 years, pediatric investigational sites in our network have participated in actually 24 completed studies.

The indications are those commonly encountered in pediatric practices and outpatient clinics. Feasibility surveys were conducted in each case (black bars).

It was never possible to recruit all the children who were previously calculated during feasibility questionning to be possibly recruited. Nevertheless, 79% of the announced subjects could be included in vaccination studies. Only 1% oft he children dropped out In the case of the allergy and asthma studies, intensive screening was necessary in order to obtain the necessary number of subjects for the studies. Here in the middle 51% of announced subjects could be included in the studies, whereby a dropout of 21% was observed.

Scientific publications exist for many studies in which NETSTAP Centers participated. They are named below. Where the publications are missing, we mostly have official final reports by the sponsors.

Here you will find an overview of our studies and their characteristics:

Ongoing studies

• Sublingual immunotherapy study (2018 – 2021, ongoing)

• Phase IIa vaccination study (2019 – 2021, ongoing)

• Phase III vaccination study (2019 – 2021, ongoing)

Planned studies

• SIT studies in the context of TAV

• Allergy prevention studies

• further vaccine studies

• spec. pediatric indication

Completed studies

• MenQuadfi_Pooled Naive toddlers_Poster_ECCMID2022_4April202

• Side effects during subcutaneous immunotherapy (SCIT) in children with allergic diseases. (2017)

• Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study (2016)

• Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial (2012).

• High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study (2012)

• Safety an efficacy in adults and children of SQ-standardised mite allergen tablet for sublingual immunotherapy (2009)

• Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children (2007)

• Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms (2004)